Clinical trial · Observational
Significance of Immunohistochemical Expression of Fascin-1 in Colorectal Carcinoma
NCT05553080CI-TRIAL-00065530completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Colorectal carcinoma is a major health problem. As a malignant tumor, the malignant potential of colorectal carcinoma is based mainly on its ability to metastasis to different sites. Fascin-1 is an actin binding protein which is involved in reconstruction of intracellular actin network, the latter enforces the neoplastic cell to invade surrounding structures.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer of Colon | Malignant Colon Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Immunohistochemistry | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Evaluation of immunohistochemical staining of colorectal carcinoma by Fascin-1
- timeFrame
- September , 2022
- description
- correlation of different levels of Fascin-1 expression to patients' ages, sexes, tumor stage, nodal metastasis, vascular and perineural invasion.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 30 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * All cases of colorectal carcinoma. Exclusion Criteria: * cases diagnosed on basis of lower endoscopic biopsies or local resections without radical colectomy. * Patients with preopoerative history of chemo or radiotherapy. * Patients with poor clinical data.
References
Publications (0)
Data not yet available
No reference posted for this study.